In forceAmendedAs enactedCurrent version · As enactedSee versions on Singapore Statutes Online(opens the publisher’s site)
Subsidiary Legislation · As enacted
Subsidiary Legislation · As enacted
Official textFrom Singapore Statutes Online, unchanged
This Order is the Interpretation (Health Sciences Authority Act — Fees) Order 2017 and comes into operation on 11 October 2017.
In this Order —“Authority” means the Health Sciences Authority established under section 3 of the Health Sciences Authority Act 2001;“cell, tissue or gene therapy product” means a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Health Products Act 2007;“medical device” means a health product categorised as a medical device in the First Schedule to the Health Products Act 2007.
“Authority” means the Health Sciences Authority established under section 3 of the Health Sciences Authority Act 2001;
“cell, tissue or gene therapy product” means a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Health Products Act 2007;
“medical device” means a health product categorised as a medical device in the First Schedule to the Health Products Act 2007.
The fees specified in the second column of the Schedule are payable to the Authority for the consultancy services under section 12(d) of the Health Sciences Authority Act 2001 specified opposite in the first column.